BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The most effective method to Offset Album Rates with Liquidity Needs - 2Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- 3New science points to 4 distinct types of autism
- 4Air Force made critical errors during October 7 massacre, investigator says
- 5Nature's Treats: 10 Organic products That Lift Prosperity
- 6 Web-based Course Stages for Successful Learning and Educating
- NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- 4 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- Ukraine demands army of 800,000 under peace plan
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- The Best 15 Applications for Efficiency and Association
- Evaluated Smartwatches for Wellness Devotees
- Muslim Brotherhood stole half a billion dollars in Gaza donations, Arab sources reveal
